ArticleNature reviews. Clinical oncology2018
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Article in Nature reviews. Clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04137718 (Multicenter Observational Study for Clinicopathological Characteristics and Clinical Efficacy of Chinese Non-Small Cell Lung Cancer), which is not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter Observational Study for Clinicopathological Characteristics and Clinical Efficacy of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Management of ectopic Cushing syndrome in medullary thyroid carcinoma: from case reports to systematic literature review.Frontiers in endocrinology · 2026Pooled it
- Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Guideline
- Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.The oncologist · 2022Trial
- Outcomes of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer Treated with First-Line Non-Molecularly Targeted Therapies: A Real-World Benchmark in Europe from the RECALIB-RET Study.Advances in therapy · 2026Article
- Article
- Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance.The American journal of pathology · 2025Review
- New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib.Frontiers in genetics · 2025Article
- Real-World Outcomes of SelectiveCancers · 2024Article
- Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.Cell communication and signaling : CCS · 2024Review
- Efficacy and safety of selpercatinib in treating RET-altered MTC: A single-arm meta-analysis.Heliyon · 2024Article
- Characteristics and Survival Outcomes of Patients With MetastaticJCO precision oncology · 2024Article
- Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.Nature cancer · 2023Article
- Structural and dynamic determinants for highly selective RET kinase inhibition reveal cryptic druggability.Journal of advanced research · 2023Article
- The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients.Journal of cancer research and clinical oncology · 2023Article
- Hereditary cancer syndromes.World journal of clinical oncology · 2023Review
- Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification.Acta neuropathologica · 2023Article
- Precision oncology with selective RET inhibitor selpercatinib inTherapeutic advances in medical oncology · 2023Review
- Review
- A critical ETV4/Twist1/Vimentin axis in Ha-RAS-induced aggressive breast cancer.Cancer gene therapy · 2022Article
Corrections and comments
- Erratum for
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This corrects the article DOI: 10.1038/nrclinonc.2017.175.
Identifiers
29182164What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.